Tango Therapeutics Inc (TNGX)

EBITDA

-$54.92M

Quarterly · Period ending: · USD

TNGX logo

TNGX EBITDA

Latest reported-$54.92M
TNGX Quarterly EBITDA (-$7.90M → -$54.92M)
High-resolution chart · PNG

TNGX ebitda history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Tango Therapeutics Inc EBITDA — Quarterly (USD)
Period endingEBITDA (USD)
-54,915,000
-45,050,000
-38,325,000
16,429,000
-38,193,000
-39,220,000
-37,001,000
-28,491,000
-24,854,000
-37,249,000
-30,099,000
-21,627,000
-20,042,000
-27,427,000
-28,439,000
-28,633,000
-24,543,000
-24,899,000
-21,613,000
-19,303,000
-4,302,000
-11,828,000
-8,674,000
-26,570,000
-8,266,000
-7,900,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.